Japanese Logistics Stock News

TSE:5857
TSE:5857Metals and Mining

Undiscovered Gems in Asia to Watch This July 2026

As global markets navigate through geopolitical tensions and fluctuating oil prices, the Asian market has shown resilience, with indices like China's CSI 300 Index and Japan's Nikkei 225 Index posting gains despite broader regional uncertainties. In this dynamic environment, identifying promising small-cap stocks can be pivotal for investors seeking to capitalize on growth opportunities within Asia's evolving economic landscape.
TSE:7460
TSE:7460Retail Distributors

Asian Dividend Stocks To Enhance Your Investment Portfolio

Amidst global economic uncertainties and fluctuating oil prices, Asian markets have shown resilience with notable advancements in key indices, such as Japan's Nikkei 225 and China's CSI 300. In this dynamic environment, dividend stocks can offer a stable income stream, making them an attractive option for investors seeking to enhance their portfolios through consistent returns.
TSE:8424
TSE:8424Diversified Financial

Fuyo General Lease (TSE:8424) Files ¥300b Bond Shelf, Is The Stock Fully Valued?

Fuyo General Lease (TSE:8424) has filed a shelf registration for up to ¥300 billion in bonds, a move that puts a sizable funding option in place and draws attention to its capital structure. See our latest analysis for Fuyo General Lease. At a share price of ¥4,520.0, Fuyo General Lease has seen recent momentum build, with a 7 day share price return of 4.03% and a 30 day share price return of 6.73%. Its 1 year total shareholder return of 14.86% and 5 year total shareholder return of 122.61%...
TSE:6098
TSE:6098Professional Services

Is AI‑Led Hiring Innovation Altering The Investment Case For Recruit Holdings (TSE:6098)?

In recent months, Recruit Holdings has drawn attention as analysts’ cash flow models and earnings multiples suggest its shares may be trading below intrinsic value, even as some broader valuation checks remain mixed. An interesting angle is how the company’s push into AI-powered and data-centric hiring solutions is reshaping expectations for its long-term role in global talent matching, despite current softness in labor demand and slower uptake of platforms like Indeed PLUS. We’ll now...
TSE:3626
TSE:3626IT

Is TISI’s Back‑Office Spin Into a Subsidiary Refining Its Investment Story (TSE:3626)?

TISI Inc. previously convened a board meeting on July 24, 2026, to consider having a wholly owned subsidiary succeed certain back-office operations via an absorption-type company split effective October 1, 2026. This potential shift of back-office functions into a subsidiary could alter TISI’s operational structure, with implications for efficiency, cost visibility, and management focus. Next, we will examine how this planned absorption-type company split of back-office operations may...
TSE:8316
TSE:8316Banks

Sumitomo Mitsui Financial Group (TSE:8316) Extends Its Rally, Is The Premium Already Too Rich?

Recent share performance has put Sumitomo Mitsui Financial Group (TSE:8316) on many investors’ radar, with the stock up around 12% over the past month and about 33% in the past 3 months. See our latest analysis for Sumitomo Mitsui Financial Group. At a share price of ¥7,161, Sumitomo Mitsui Financial Group has posted a 12.05% 1 month share price return and a 1 year total shareholder return of 85.91%, alongside a multi year total shareholder return that is several times the initial investment...
TSE:4502
TSE:4502Pharmaceuticals

Can Takeda Pharmaceutical (TSE:4502) Trade At A Discount On New Phase 3 Psoriasis Data?

Takeda Pharmaceutical (TSE:4502) has drawn fresh attention after releasing new Phase 3 data for its oral TYK2 inhibitor zasocitinib in adults with moderate to severe plaque psoriasis, highlighting meaningful skin clearance across difficult areas. See our latest analysis for Takeda Pharmaceutical. Together with the zasocitinib update and the recent plasma collaboration in Indonesia, Takeda Pharmaceutical’s 11.03% 1 month share price return and 35.86% 1 year total shareholder return suggest...
TSE:6532
TSE:6532Professional Services

Baycurrent (TSE:6532) Earnings Strength Raises The Question Of Whether The Stock Is Fully Valued

Why Baycurrent’s Latest Earnings Matter for Investors Baycurrent (TSE:6532) has drawn fresh attention after reporting first quarter earnings, with sales of ¥44,576 million, net income of ¥10,733 million, and basic earnings per share of ¥70.99 from continuing operations. These figures compare with sales of ¥34,307 million, net income of ¥9,016 million, and basic earnings per share of ¥59.32 in the same quarter a year earlier, giving investors updated context on Baycurrent’s consulting focused...
TSE:6946
TSE:6946Electronic

Nomura Micro Science Among 3 Asian Stocks Priced Below Estimated Value

Amidst a backdrop of geopolitical tensions and fluctuating oil prices, Asian markets have shown resilience, with indices like the Nikkei 225 and CSI 300 making notable gains. In this environment, identifying undervalued stocks can be crucial for investors looking to capitalize on market inefficiencies; Nomura Micro Science is among those currently priced below their estimated value.
TSE:8370
TSE:8370Banks

CIMC Enric Holdings And 2 Other Asian Dividend Stocks To Consider

As Asian markets navigate the complexities of geopolitical tensions and fluctuating oil prices, investors are increasingly focused on finding stable returns amidst volatility. In this environment, dividend stocks like CIMC Enric Holdings offer a potential avenue for income generation, providing a buffer against market uncertainties while contributing to portfolio stability.
TSE:6134
TSE:6134Machinery

3 Asian Stocks Estimated To Be 39.2% To 44.2% Below Intrinsic Value

Amidst the global market's fluctuations and geopolitical tensions, Asian markets have shown resilience with strategic investments in sectors like AI and semiconductors. In this environment, identifying undervalued stocks becomes crucial as investors seek opportunities that are priced below their intrinsic value, offering potential for growth when market conditions stabilize.
TSE:4519
TSE:4519Pharmaceuticals

Chugai Pharmaceutical (TSE:4519) Stock Net Margin Strength Challenges Cost Pressure Concerns

Chugai Pharmaceutical (TSE:4519) has reported Q2 2026 revenue of ¥341,584 million and basic EPS of ¥70.69, while trailing twelve month revenue stands at ¥1.3 trillion and EPS at ¥286.43, framed by earnings growth of 19.2% over the past year. The company has seen quarterly revenue move from ¥290,004 million and EPS of ¥59.04 in Q2 2025 to ¥341,584 million and EPS of ¥70.69 in Q2 2026, with trailing twelve month EPS rising from ¥240.31 to ¥286.43 over the same comparison points. Together with a...